Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Summarizes 2021 Milestones, Outlines 2022 Plans and Expectations, in Annual Letter to Shareholders

February 8, 2022 13:56:10
  • In 2021, Lexaria conducted several main studies evaluating DehydraTECH-processed CBD and nicotine
  • The company has big plans for 2022, a year it expects to undertake three ground-breaking studies
  • Lexaria hopes these three major studies will generate sufficient data to support either regulated IND-type applications or to stimulate corporate partnerships
  • The company is eying larger national and international applications for DehydraTECH with the aim of generating revenue through licensing fees and royalties

For Lexaria Bioscience (NASDAQ: LEXX), a drug delivery company whose patented DehydraTECH(TM) technology has proven effective in improving bioavailability, speed of onset, and efficiency of orally-delivered fat-soluble active molecules and pharmaceuticals, 2021 was a year of myriad milestones. In an annual letter to shareholders, company CEO Chris Bunka underlined that January 2021 marked the birth of a modern version of the company (https://cnw.fm/Hli8Z).

“During 2021, we completed research & development (‘R&D’) and validating work equal to or greater than all the combined amount previously completed since…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.

Receive Text Alerts from CBDWireText “Cannabis” to 21000

For more information please visit https://www.cbdwire.com and or https://CBDWire.News

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Denver, Colorado
303.498.7722 Office

CBDWire is part of the InvestorBrandNetwork.